The state of Texas currently has 42 active clinical trials seeking participants for Type 2 Diabetes research studies. These trials are conducted in various cities, including Houston, Dallas, San Antonio and Austin.
A Research Study to Investigate the Effects of CagriSema Compared to Placebo in People With Type 2 Diabetes and Painful Diabetic Peripheral Neuropathy
NCT06797869
Recruiting
This study will look at the effects of CagriSema in people with both type 2 diabetes and painful diabetic peripheral neuropathy, compared to placebo. Participants will either get an active medicine or a "dummy" medicine (placebo). Which treatment participants get is decided by chance. In this study the active, investigational medicine is called CagriSema. Doctors cannot yet prescribe CagriSema. For each participant, the study will last for about 10 months.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/20/2025
Locations: Radiance Clinical Research, Lampasas, Texas +1 locations
Conditions: Diabetes Mellitus, Type 2, Diabetic Peripheral Neuropathy
Register for Updates
Effect of Retatrutide Compared With Placebo in Participants With Type 2 Diabetes and Moderate or Severe Renal Impairment, With Inadequate Glycemic Control on Basal Insulin, With or Without Metformin and/or SGLT2 Inhibitor (TRANSCEND-T2D-3)
NCT06297603
Recruiting
The purpose of this study is to investigate the efficacy and safety of retatrutide compared with placebo in participants with Type 2 Diabetes and renal impairment, with inadequate glycemic control on basal insulin alone or a combination of basal insulin with or without metformin and/or sodium-glucose cotransporter-2 (SGLT2) inhibitor. The study will last about 14 months and may include up to 22 visits.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/17/2025
Locations: Velocity Clinical Research, Dallas, Dallas, Texas +5 locations
Conditions: Type 2 Diabetes
Register for Updates
Gastroparesis Registry 4
NCT05846802
Recruiting
The Gastroparesis Registry 4 (GpR4) is an observational study of patients with symptoms of gastroparesis (Gp) and functional dyspepsia (FD) with either delayed or normal gastric emptying. To better understand these disorders, this registry will capture demographic, clinical, physiological, questionnaire, and patient outcome data to characterize the patients and their clinical course. Participants will complete several questionnaires, complete a nutrient drink test and have a gastric emptying stu... Read More
Gender:
ALL
Ages:
Between 18 years and 85 years
Trial Updated:
04/16/2025
Locations: Texas Tech University Health Science Center (TTUHSC), El Paso, Texas
Conditions: Gastroparesis, Gastroparesis Nondiabetic, Gastroparesis Due to Diabetes Mellitus Type I, Gastroparesis Due to Diabetes Mellitus Type II, Functional Disorder of Gastrointestinal Tract, Gastro-Intestinal Disorder
Register for Updates
A Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity
NCT06037252
Recruiting
The main purpose of this study is to learn more about the safety and efficacy of investigational tirzepatide doses in participants with Type 2 diabetes and obesity that are already taking metformin. The study will last for about 89 weeks.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
04/16/2025
Locations: Juno Research, Houston, Texas +1 locations
Conditions: Type 2 Diabetes, Obesity
Register for Updates
A Study of Dulaglutide (LY2189265) 3.0 mg and 4.5 mg in Pediatric Participants With Type 2 Diabetes Mellitus (AWARD-PEDS PLUS)
NCT06739122
Recruiting
The main purpose of this study is to evaluate additional dosing options for dulaglutide in pediatric participants with Type 2 Diabetes. Participation in this study will last about 8 months.
Gender:
ALL
Ages:
Between 10 years and 17 years
Trial Updated:
04/16/2025
Locations: Texas Childrens Hospital, Houston, Texas
Conditions: Type 2 Diabetes
Register for Updates
Glycemic and Weight Loss Effects of GLP-1R Agonist Therapy in Subjects With Spinal Cord Injury and Type 2 Diabetes
NCT06706284
Recruiting
It is not known whether a new diabetes drug, semaglutide, is an effective treatment for type 2 diabetes for persons with spinal cord injury (SCI), a population at higher risk for this condition. Therefore, this study looks at the effect of semaglutide on glucose levels in the body and other information about type 2 diabetes and obesity.
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
04/15/2025
Locations: University Health - Texas Diabetic Institute, San Antonio, Texas +1 locations
Conditions: Spinal Cord Injuries, Type 2 Diabetes
Register for Updates
A Study of CT-388 in Participants Who Are Overweight or Obese With Type 2 Diabetes Mellitus
NCT06628362
Recruiting
This is a multi-center, randomized, double-blind, placebo-controlled, parallel group dose-finding study to evaluate the efficacy and safety of CT-388 at low, middle, and high doses in participants who are overweight or obese with Type 2 diabetes mellitus (T2DM).
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
04/14/2025
Locations: Velocity Clinical Research - Dallas, Dallas, Texas +3 locations
Conditions: Overweight or Obese, Type 2 Diabetes Mellitus (T2DM)
Register for Updates
A Study of REACT in Subjects With Type 2 Diabetes Mellitus and Chronic Kidney Disease
NCT05099770
Recruiting
The purpose of this study is to assess the safety and efficacy (including durability) of up to 2 REACT injections given 3 months (+30 days) apart and delivered percutaneously into biopsied and non-biopsied contralateral kidneys in participants with T2DM and CKD.
Gender:
ALL
Ages:
Between 30 years and 80 years
Trial Updated:
04/09/2025
Locations: Pioneer Research Solutions, Inc., Cypress, Texas +8 locations
Conditions: Type 2 Diabetes Mellitus, Chronic Kidney Diseases
Register for Updates
SGLT2 Inhibitors, Ketones, and Cardiovascular Benefit Research Plan
NCT05057806
Recruiting
The study team will examine the effects of SGLT2i (and SGLT2i-induced increases in plasma ketone concentrations) on skeletal muscle and cardiac ketone uptake, skeletal muscle bioenergetics, cardiopulmonary exercise capacity, and patient-reported functional outcomes.
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
03/25/2025
Locations: Texas Diabetes Institute - University Health System, San Antonio, Texas +1 locations
Conditions: Type2 Diabetes, Heart Failure With Preserved Ejection Fraction
Register for Updates
Diabetes Prevention in Hispanic Adults Using Constant Glucose Monitors
NCT06864728
Recruiting
The purpose of the study is twofold: to see the impact of your environmental stress on daily glucose changes and to create an intervention using CGM to potentially decrease risk for diabetes. The aim of this study to develop an intervention to prevent diabetes in the Hispanic community and inform policies about social determinants of health.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/06/2025
Locations: University of Texas at Austin, Austin, Texas
Conditions: Prediabetes / Type 2 Diabetes
Register for Updates
Safety and Effectiveness of Endoscopic Intestinal Re-Cellularization Therapy in Individuals With Type II Diabetes
NCT06267391
Recruiting
This study is designed to evaluate the safety and effectiveness of endoscopic intestinal re-cellularization therapy in individuals with type 2 diabetes (T2D) inadequately controlled on non-insulin glucose-lowering medications.
Gender:
ALL
Ages:
Between 22 years and 70 years
Trial Updated:
03/03/2025
Locations: Velocity Clinical Research - Austin, Austin, Texas +13 locations
Conditions: Type 2 Diabetes Mellitus, Type2diabetes, Diabetes Mellitus, Type 2, Diabetes, Type 2 Diabetes
Register for Updates
NT-ProBNP-based Heart Failure Screening and Prevention Trial in Patients with Type 2 Diabetes: STRONG-DM Study
NCT06593327
Recruiting
A pragmatic, randomized clinical trial to evaluate the effect of a heart failure (HF) risk assessment and prevention strategy incorporating HF clinical risk scores (WATCH-DM) with cardiac biomarker (NT-proBNP) paired with a clinical decision support tool to implement an intensive prevention strategy among patients with high risk focused on implementation of evidence-based HF preventive therapies.
Gender:
ALL
Ages:
All
Trial Updated:
02/24/2025
Locations: University of Texas Southwestern Medical Center, Dallas, Texas
Conditions: Type 2 Diabetes, Diabetic Cardiomyopathy, Heart Failure, Cardiometabolic Diseases
Register for Updates